Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants - Report - MDSpire

Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants

  • By

  • Anne-Marie Rick

  • Jennifer Deese

  • Jessica E. Kerr

  • Jonathan Hui

  • Hui Liu

  • Guan Yu

  • Chung-Chou H. Chang

  • Nicole Fazio

  • Muhammad H. Tahir

  • Rachael Bieltz

  • Anjani Ravindra

  • Christina Megli

  • Arun Jeyabalan

  • Sarah J. Pugh

  • Divya Patel

  • Rong Fan

  • Jessica E. Atwell

  • Alejandro Cané

  • Judith M. Martin

  • June 5, 2026

  • 0 min

Share

Impact of Maternal Vaccination Against Respiratory Syncytial Virus Prefusion F

Overview

The study evaluates the effectiveness of the RSV prefusion F vaccine administered to pregnant individuals in reducing RSV-associated acute respiratory illness (ARI) and lower respiratory tract disease (LRTD) in infants. Preliminary findings indicate vaccine efficacy against RSV-associated hospitalizations in infants aged 0 to 90 days.

Background

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants, leading to millions of hospitalizations and deaths annually. The recent approval of the RSV prefusion F vaccine aims to provide protection to infants through maternal immunization.

Data Highlights

OutcomeVaccine EffectivenessConfidence Interval
RSV-associated medically attended LRTD57.6%95% CI, 31.3%-74.6%
Severe LRTD82.4%95% CI, 57.5%-93.9%
RSV-associated hospitalization69.7%95% CI, 37.1%-86.7%

Key Findings

  • The RSV prefusion F vaccine demonstrated 57.6% efficacy against RSV-associated medically attended LRTD in infants.
  • For severe LRTD, the vaccine showed an efficacy of 82.4%.
  • Vaccine effectiveness against RSV-associated hospitalization was reported at 69.7%.
  • The study utilized a test-negative design to estimate vaccine effectiveness, minimizing bias.
  • Data were collected from a semiclosed health system in Western Pennsylvania.

Clinical Implications

The findings suggest that maternal vaccination with RSVpreF can significantly reduce the incidence of RSV-related hospitalizations in infants. Clinicians should consider the timing of vaccination during pregnancy to maximize the protective benefits for newborns.

Conclusion

The interim analysis indicates that maternal vaccination with RSVprefusion F is effective in reducing RSV-associated acute respiratory illness and hospitalization in infants.

Related Resources & Content

  1. CDC, MMWR, 2023 -- Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices
  2. JAMA Network Open, 2026 -- Clarification of Findings in Key Points
  3. Open Forum Infectious Diseases -- Characterization of Respiratory Syncytial Virus Illness and Antibody Responses in Pregnant Women and Infants in the United States and South Africa
  4. conexiant — RSV Prevention Tied to Lower Infant Acute Care Use
  5. conexiant — Nirsevimab Linked to Lower Infant Hospitalization Risk Than Maternal Vaccine
  6. RSV Prevention Tied to Lower Infant Acute Care Use
  7. Nirsevimab Linked to Lower Infant Hospitalization Risk Than Maternal Vaccine
  8. RSV Vaccine Guidance for Pregnant Women | RSV | CDC
  9. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 | MMWR
  10. Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025 | MMWR

Original Source(s)

Related Content